Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
DFTXthis companyDefinium Therapeutics, Inc.	$34.59	-6.5×	3.6×	0×	-5.26×	-91.2%	0.0%	0.0%	0.0%	-55.3%	-44.5%	-11.0%	0×	1.45×	-30.34×	6.29×	0.0%	3	12.28	2	C
ANROAlto Neuroscience, Inc.	$27.89	-8.13×	3.4×	0×	-5.68×	-73.1%	0.0%	0.0%	0.0%	-41.8%	-38.2%	-10.1%	0.03×	2.86×	-26.88×	15.69×	0.0%	2	13.38	2	C+
AXSMAxsome Therapeutics, Inc.	$133.82	-49.63×	102.9×	14.23×	-53.57×	-423.3%	92.6%	-26.5%	-28.7%	-207.5%	-44.0%	-1.0%	2.73×	0.49×	-25.81×	1.55×	0.0%	3	4.25	1	D+
LBRXLB Pharmaceuticals Inc Common Stock	$42.38	-22.26×	1.87×	0×	-12.72×	-75.2%	0.0%	0.0%	0.0%	-8.4%	-9.9%	-6.3%	0.01×	9.91×	0×	41.44×	0.0%	2	25.27	2	C+
MPLTMapLight Therapeutics, Inc.	$7.43	-4.8×	1.69×	0×	-4.56×	-86.3%	0.0%	0.0%	0.0%	-35.2%	-36.4%	-17.9%	0.01×	0.25×	0×	20.01×	0.0%	2	5.7	2	C
NERVMinerva Neurosciences, Inc.	$2.46	-0.12×	-0.24×	0×	-0.06×	-15.7%	0.0%	0.0%	0.0%	208.5%	-15.8%	-39708.5%	-0.46×	0.06×	0×	36.29×	0.0%	1	-24.23	2	C+
Peer median	—	-8.13×	1.87×	0×	-5.68×	-75.2%	0.0%	0.0%	0.0%	-35.2%	-36.4%	-10.1%	0.01×	0.49×	0×	20.01×	0.0%	2	5.7	2	—